Prelude Therapeutics Inc (PRLD): Next-Year EPS Estimate 58.80%
As of 2026-05-04, Prelude Therapeutics Inc (PRLD) has a next-year EPS growth estimate of 58.80%.
On 2026-04-27, analyst consensus for PRLD's next-year EPS growth shifted from 54.29% to 58.80% — a positive change of 4.51 percentage points. The revised estimate has been sustained across 6 subsequent trading sessions. Current-year growth is projected at 39.79%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 58.80%
- EPS growth this year
- 39.79%
- EPS next quarter (est)
- -$0.25
- Last price
- $4.63
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-05-04 | 58.80% | 39.79% | -$0.25 | $4.63 |
| 2026-05-03 | 58.80% | 39.79% | -$0.25 | $4.70 |
| 2026-04-30 | 58.80% | 39.79% | -$0.25 | $5.23 |
| 2026-04-29 | 58.80% | 39.79% | -$0.25 | $4.27 |
| 2026-04-28 | 58.80% | 39.79% | -$0.25 | $4.39 |
| 2026-04-27 | 58.80% | 39.79% | -$0.25 | $4.52 |
| 2026-04-26 | 54.29% | 45.74% | -$0.24 | $4.70 |
| 2026-04-24 | 54.29% | 45.74% | -$0.24 | $4.70 |
| 2026-04-23 | 54.29% | 45.74% | -$0.24 | $4.40 |
| 2026-04-22 | 54.29% | 45.74% | -$0.24 | $4.31 |
| 2026-04-21 | 54.29% | 45.74% | -$0.24 | $4.62 |
| 2026-04-20 | 54.29% | 45.74% | -$0.24 | $4.51 |
| 2026-04-19 | 54.29% | 45.74% | -$0.24 | $4.44 |
| 2026-04-16 | 54.29% | 45.74% | -$0.24 | $4.43 |
| 2026-04-15 | 54.29% | 45.74% | -$0.24 | $5.52 |
| 2026-04-14 | 54.29% | 45.74% | -$0.24 | $4.40 |
| 2026-04-13 | 54.29% | 45.74% | -$0.24 | $4.37 |
| 2026-04-12 | 54.29% | 45.74% | -$0.24 | $4.08 |
| 2026-04-10 | 54.29% | 45.74% | -$0.24 | $4.22 |
| 2026-04-09 | 54.29% | 45.74% | -$0.24 | $4.40 |
| 2026-04-08 | 54.29% | N/A | -$0.24 | $4.22 |
| 2026-04-07 | 54.29% | N/A | -$0.24 | $4.40 |
| 2026-04-06 | 54.29% | N/A | -$0.24 | $4.40 |
| 2026-04-05 | 54.29% | N/A | -$0.24 | $3.46 |
| 2026-04-03 | 54.29% | N/A | -$0.24 | $4.40 |
| 2026-04-02 | 54.29% | N/A | -$0.24 | $4.40 |
| 2026-04-01 | 54.29% | N/A | -$0.24 | $4.40 |
| 2026-04-01 | 54.29% | N/A | N/A | $3.42 |
| 2026-04-01 | 54.29% | N/A | N/A | $3.45 |
| 2026-04-01 | 54.29% | N/A | N/A | $3.45 |
Screen Performance
Aggregate stats across all 1781 tickers our top-EPS-revision screen has flagged over the past 71 days.
- Median return since detection
- +3.8%
- % of tickers in the green
- 58%
- Median return on winners
- +18.5%
- Large revisions captured
- 788
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Prelude Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-05-04, Prelude Therapeutics Inc (PRLD) has a next-year EPS growth estimate of 58.80%, based on analyst consensus.
When was the latest EPS estimate revision for PRLD?▾
The most recent revision occurred on 2026-04-27, when analysts adjusted the next-year EPS growth estimate from 54.29% to 58.80%.
What sector and industry does Prelude Therapeutics Inc belong to?▾
Prelude Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. PRLD appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Prelude Therapeutics Inc (PRLD) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports